Document Detail

A case study of trastuzumab treatment for metastatic breast cancer in pregnancy: fetal risks and management of cerebral metastases.
MedLine Citation:
PMID:  21806575     Owner:  NLM     Status:  MEDLINE    
Trastuzumab increases survival amongst women with human epidermal growth factor receptor (HER)-2 receptor positive metastatic breast cancer, but maternal and fetal risks are associated with advanced disease and its treatment in pregnancy. We present a case of a primigravid with HER-2 positive metastatic breast cancer who received trastuzumab throughout pregnancy. She presented with cerebral metastases, requiring surgical decompression and resection. Reversible oligohydramnios developed during pregnancy. Fetal safety data on trastuzumab in pregnancy is limited, but case reports suggest a recurring pattern of (mostly reversible) oligohydramnios.
Christine L Mandrawa; Josephine Stewart; Gavin C Fabinyi; Susan P Walker
Related Documents :
24790515 - Can maternal serum c-reactive protein levels predict successful labour induction with i...
24959475 - Small intestine ischaemia due to volvulus during pregnancy.
24894105 - Fertility, ovarian failure, and pregnancy outcome in sle patients treated with intraven...
23531705 - Clomiphene citrate or letrozole as first-line ovulation induction drug in infertile pco...
11491375 - Pregnancy following transfer of cryopreserved-thawed embryos that had been a result of ...
25395745 - A comparative study between cleavage stage embryo transfer at day 3 and blastocyst stag...
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2011-05-12
Journal Detail:
Title:  The Australian & New Zealand journal of obstetrics & gynaecology     Volume:  51     ISSN:  1479-828X     ISO Abbreviation:  Aust N Z J Obstet Gynaecol     Publication Date:  2011 Aug 
Date Detail:
Created Date:  2011-08-16     Completed Date:  2012-01-10     Revised Date:  2013-05-08    
Medline Journal Info:
Nlm Unique ID:  0001027     Medline TA:  Aust N Z J Obstet Gynaecol     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  372-6     Citation Subset:  IM    
Copyright Information:
© 2011 The Authors. Australian and New Zealand Journal of Obstetrics and Gynaecology © 2011 The Royal Australian and New Zealand College of Obstetricians and Gynaecologists.
University Department of Obstetrics and Gynaecology, Mercy Hospital for Women, Victoria, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal, Humanized / administration & dosage*
Antineoplastic Agents / administration & dosage*
Bone Neoplasms / drug therapy,  secondary
Brain Neoplasms / metabolism,  secondary,  surgery*
Breast Neoplasms / drug therapy*,  metabolism,  pathology
Carcinoma, Ductal, Breast / drug therapy*,  metabolism,  secondary
Decompression, Surgical
Infant, Newborn
Liver Neoplasms / drug therapy,  secondary
Magnetic Resonance Imaging
Oligohydramnios / etiology,  physiopathology
Pregnancy Complications, Neoplastic*
Pregnancy Outcome
Receptor, erbB-2 / metabolism*
Risk Factors
Reg. No./Substance:
0/Antibodies, Monoclonal, Humanized; 0/Antineoplastic Agents; EC, erbB-2; P188ANX8CK/trastuzumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Vitamin D status and its predictive factors in pregnancy in 2 Australian populations.
Next Document:  Normal ranges for fetal nasal bone length determined by ultrasound at 18-20?weeks of gestation in a ...